Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OXER1 | Q8TDS5 | 4/20 | 0.54 |
| ▸ | FPR2 | P25090 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | LTB4R2 | Q9NPC1 | 2/20 | 0.48 |
| ▸ | LTB4R | Q15722 | 1/20 | 0.48 |
| ▸ | FAAH | O00519 | 4/20 | 0.46 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.42 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.42 |
| ▸ | RXRA | P19793 | 1/20 | 0.42 |
| ▸ | PPARG | P37231 | 1/20 | 0.42 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.41 |
| ▸ | PPARA | Q07869 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3406687 | 1.00 | OXER1 (0.54) | OXER1FPR2ALDH1A1LTB4R2LTB4R | |
| SCHEMBL16675136 | 1.00 | OXER1 (0.54) | OXER1FPR2ALDH1A1LTB4R2LTB4R | |
| SCHEMBL3406682 | 1.00 | OXER1 (0.54) | OXER1FPR2ALDH1A1LTB4R2LTB4R | |
| SCHEMBL12151577 | 1.00 | OXER1 (0.54) | OXER1FPR2ALDH1A1LTB4R2LTB4R | |
| SCHEMBL3404679 | 1.00 | OXER1 (0.54) | OXER1FPR2ALDH1A1LTB4R2LTB4R | |
| SCHEMBL17528600 | 1.00 | OXER1 (0.54) | OXER1FPR2ALDH1A1LTB4R2LTB4R | |
| SCHEMBL20085622 | 1.00 | OXER1 (0.54) | OXER1FPR2ALDH1A1LTB4R2LTB4R | |
| SCHEMBL16675135 | 1.00 | OXER1 (0.54) | OXER1FPR2ALDH1A1LTB4R2LTB4R | |
| SCHEMBL3406717 | 1.00 | OXER1 (0.54) | OXER1FPR2ALDH1A1LTB4R2LTB4R | |
| SCHEMBL16677125 | 0.95 | OXER1 (0.53) | OXER1FPR2ALDH1A1LTB4R2LTB4R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160256521-A1 | TOPICAL FORMULATIONS AND USES THEREOF | OCULAR TECHNOLOGIES SARL (CH) | 2016-09-08 | — | — | US | disclosed |
| US-9315447-B2 | Compositions and methods for the treatment of inflammation | A.T. Resolve Sarl (CH) | 2016-04-19 | — | — | US | disclosed |
| US-20150165048-A1 | TOPICAL FORMULATIONS AND USES THEREOF | SUN PHARMA GLOBAL FZE (AE) | 2015-06-18 | — | — | US | disclosed |
| US-20140275247-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF INFLAMMATION | A.T. Resolve Sarl (CH) | 2014-09-18 | — | — | US | disclosed |
| US-8673881-B2 | Compositions and methods for the treatment of inflammation | A.T. Resolve Sarl (CH) | 2014-03-18 | — | — | US | disclosed |
| US-20120122816-A1 | COMPOSITIONS AND METHODS FOR ORGAN PRESERVATION | RESOLVYX PHARMACEUTICALS, INC. (US) | 2012-05-17 | — | — | US | disclosed |
| US-20120101061-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF INFLAMMATION | A.T. Resolve Sarl (CH) | 2012-04-26 | — | — | US | disclosed |
| US-20110190242-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF INFLAMMATORY DISEASE | RESOLVYX PHARMACEUTICALS, INC. (US) | 2011-08-04 | — | — | US | disclosed |
| US-20090137527-A1 | Compositions and methods for modulating immune function | RESOLVYX PHARMACEUTICALS, INC. (US) | 2009-05-28 | — | — | US | disclosed |
| US-20080161274-A1 | Compounds and methods for inhibition of bone loss | RESOLVYX PHARMACEUTICALS, INC. (US) | 2008-07-03 | — | — | US | disclosed |
| US-20080161275-A1 | Compositions and methods for the treatment of inflammatory disease | RESOLVYX PHARMACEUTICALS, INC. (US) | 2008-07-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120101061-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF INFLAMMATION | ALOX15B, ALOX5, ALOX12 | OXER1 273/4885FPR2 22/4885ALDH1A1 2449/4885 |
| US-20080161275-A1 | Compositions and methods for the treatment of inflammatory disease | ALOX15B, ALOX12, ALOX15 | OXER1 140/4885FPR2 42/4885ALDH1A1 1031/4885 |
| US-20150165048-A1 | TOPICAL FORMULATIONS AND USES THEREOF | LIPA, MGLL, LIPC | OXER1 2251/4885FPR2 229/4885ALDH1A1 285/4885 |
| US-20080161274-A1 | Compounds and methods for inhibition of bone loss | ALOX15B, ALOX5, ALOX12 | OXER1 416/4885FPR2 110/4885ALDH1A1 3157/4885 |
| US-20110190242-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF INFLAMMATORY DISEASE | ALOX15B, ALOX12, ALOX15 | OXER1 167/4885FPR2 63/4885ALDH1A1 1179/4885 |
| US-20140275247-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF INFLAMMATION | ALOX15B, ALOX5, ALOX12 | OXER1 273/4885FPR2 22/4885ALDH1A1 2449/4885 |
| US-20160256521-A1 | TOPICAL FORMULATIONS AND USES THEREOF | LIPA, MGLL, LIPC | OXER1 2251/4885FPR2 229/4885ALDH1A1 285/4885 |
| US-20120122816-A1 | COMPOSITIONS AND METHODS FOR ORGAN PRESERVATION | ALOX5, ALOX15B, ALOX12 | OXER1 444/4885FPR2 442/4885ALDH1A1 176/4885 |
| US-20090137527-A1 | Compositions and methods for modulating immune function | ALOX15B, ALOX12, ALOX5 | OXER1 77/4885FPR2 114/4885ALDH1A1 2190/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.